METASTRON Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Metastron, and what generic alternatives are available?
Metastron is a drug marketed by Q Biomed and is included in one NDA.
The generic ingredient in METASTRON is strontium chloride sr-89. There are sixteen drug master file entries for this compound. Additional details are available on the strontium chloride sr-89 profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metastron
A generic version of METASTRON was approved as strontium chloride sr-89 by Q BIOMED on January 6th, 2003.
Summary for METASTRON
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | METASTRON at DailyMed |
Recent Clinical Trials for METASTRON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| M.D. Anderson Cancer Center | Phase 3 |
| National Cancer Institute (NCI) | Phase 3 |
| M.D. Anderson Cancer Center | Phase 2 |
US Patents and Regulatory Information for METASTRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q Biomed | METASTRON | strontium chloride sr-89 | INJECTABLE;INJECTION | 020134-001 | Jun 18, 1993 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
